CAMBRIDGE, Mass., Jan. 8, 2025 -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical-stage immunology company advancing RNA therapeutics to conquer cancer, announced today its participation at the 43rd Annual JP Morgan Healthcare Conference, taking place January 13-16, 2025.
Daniel Getts, Ph.D., CEO of Myeloid, will present on Wednesday, January 15, 2025, at 8:30 am PT. Company management will also participate in one-on-one meetings with investors during the conference.
About Myeloid Therapeutics
Myeloid Therapeutics is a clinical stage immunology company, engineering cutting-edge RNA technology to program immune cells to combat cancer and other deadly diseases. Myeloid is headquartered in Cambridge, MA.
For additional information, please visit, https://www.myeloidtx.com/ and follow us on LinkedIn and X/Twitter. For collaborative interests, write to partnering@myeloidtx.com.
Investor Contact
Amy Conrad
Juniper Point
Amy@juniper-point.com
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
